Squarepoint’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $228K | Buy |
+277,375
| New | +$262K | ﹤0.01% | 3987 |
|
|
2025
Q3 | – | Sell |
-43,253
| Closed | -$51.9K | – | 4692 |
|
|
2025
Q2 | $51.9K | Buy |
+43,253
| New | +$47.9K | ﹤0.01% | 4297 |
|
|
2024
Q4 | – | Sell |
-236,396
| Closed | -$456K | – | 5294 |
|
|
2024
Q3 | $456K | Sell |
236,396
-69,120
| -23% | -$135K | ﹤0.01% | 3169 |
|
|
2024
Q2 | $541K | Buy |
305,516
+172,738
| +130% | +$422K | ﹤0.01% | 3017 |
|
|
2024
Q1 | $360K | Buy |
132,778
+96,397
| +265% | +$233K | ﹤0.01% | 3269 |
|
|
2023
Q4 | $80.4K | Buy |
+36,381
| New | +$77.7K | ﹤0.01% | 3788 |
|
|
2023
Q2 | – | Sell |
-11,138
| Closed | -$21.7K | – | 3804 |
|
|
2023
Q1 | $21.7K | Buy |
+11,138
| New | +$22K | ﹤0.01% | 3128 |
|
|
2022
Q3 | – | Sell |
-12,492
| Closed | -$20K | – | 3219 |
|
|
2022
Q2 | $20K | Buy |
+12,492
| New | +$30.9K | ﹤0.01% | 2772 |
|
|
2022
Q1 | – | Sell |
-129,734
| Closed | -$509K | – | 3216 |
|
|
2021
Q4 | $509K | Buy |
129,734
+101,064
| +353% | +$473K | ﹤0.01% | 2132 |
|
|
2021
Q3 | $189K | Buy |
+28,670
| New | +$189K | ﹤0.01% | 2515 |
|
|
2021
Q1 | – | Sell |
-67,577
| Closed | -$405K | – | 3377 |
|
|
2020
Q4 | $405K | Buy |
67,577
+12,277
| +22% | +$80.7K | ﹤0.01% | 1971 |
|
|
2020
Q3 | $411K | Sell |
55,300
-71,127
| -56% | -$491K | 0.01% | 1580 |
|
|
2020
Q2 | $507K | Buy |
126,427
+109,351
| +640% | +$381K | 0.01% | 1310 |
|
|
2020
Q1 | $43K | Sell |
17,076
-343,643
| -95% | -$1.13M | ﹤0.01% | 1732 |
|
|
2019
Q4 | $1.26M | Sell |
360,719
-53,421
| -13% | -$188K | 0.01% | 1196 |
|
|
2019
Q3 | $1.92M | Buy |
414,140
+235,840
| +132% | +$1.86M | 0.02% | 865 |
|
|
2019
Q2 | $2.2M | Buy |
178,300
+58,992
| +49% | +$751K | 0.02% | 794 |
|
|
2019
Q1 | $1.59M | Buy |
119,308
+46,319
| +63% | +$488K | 0.02% | 877 |
|
|
2018
Q4 | $629K | Buy |
+72,989
| New | +$569K | 0.01% | 1138 |
|
|
2018
Q3 | – | Sell |
-24,795
| Closed | -$148K | – | 2102 |
|
|
2018
Q2 | $148K | Buy |
+24,795
| New | +$141K | ﹤0.01% | 1587 |
|
|
2017
Q1 | – | Sell |
-18,936
| Closed | -$138K | – | 1730 |
|
|
2016
Q4 | $138K | Buy |
+18,936
| New | +$119K | 0.01% | 1563 |
|
|
2016
Q3 | – | Sell |
-13,400
| Closed | -$121K | – | 1142 |
|
|
2016
Q2 | $121K | Buy |
+13,400
| New | +$126K | 0.01% | 962 |
|
Other funds holding LAB
LFCM
HBWM
Squarepoint's LAB Position: Q2 2026 in Review
Squarepoint opened a new position in Standard BioTools (LAB) in Q2 2026: 277,375 shares worth $228K. The stake represents ﹤0.01% of the portfolio and ranks #3987 among its holdings. This is a return to the name: Squarepoint previously reported a position in LAB as recently as Q2 2025.
Squarepoint first reported a position in LAB in Q2 2016 and has held it in 22 quarters since. The position peaked at $2.2M in Q2 2019. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.
- Squarepoint held 277,375 shares of Standard BioTools worth $228K as of Q2 2026.
- Standard BioTools was a new Squarepoint position in Q2 2026.
- Standard BioTools made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3987 holding.
- Squarepoint first reported a position in Standard BioTools in Q2 2016 and has held it in 22 quarters since.
- Squarepoint's Standard BioTools position peaked at $2.2M in Q2 2019.
- 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.